Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

Inclusion Criteria: - Informed consent obtained before any study-related activities.
Study-related activities are any procedures that are carried out as part of the study -
Male or female, age greater than or equal to 18 years at the time of signing informed
consent - Type 2 diabetes mellitus diagnosis - Treatment with metformin as antidiabetic
monotherapy - Current member of an Anthem affiliated commercial health plan - Recorded
Haemoglobin A1c value within last 90 days prior to randomization - Further intensification
with an additional antidiabetic oral or injectable medication is indicated to achieve
glycemic target at the discretion of the study physician according to approved labelling
Exclusion Criteria: - Previous randomization in this study - Treatment with any medication
for the indication of diabetes other than metformin in a period of 30 days before the day
of eligibility assessment. Temporary/emergency use of any type of insulin is allowed, as is
prior insulin treatment for gestational diabetes - Contraindications to semaglutide
according to the Food and Drug Administration approved label - Female who is pregnant,
breastfeeding or intends to become pregnant - Participation in another clinical trial